Jan Yperman Ziekenhuis

Ieper 18 trials 7 recruiting

18 Registered trials

7 Currently recruiting

Organisation

Jan Yperman Ziekenhuis

Location

Ieper, Belgium

Identifier

ORG-100041854

Address

Briekestraat 12, 8900, Belgium

Departments

05601 Urologie
Cardiology
Departement Endocrinologie-Diabetologie
Endocrinology
Haematology
Infectious Diseases department
Nephrology
Nephrology, Infectious Diseases & General Internal Medicine
Nephrology, Infectious Diseases and General Internal Medicine
Oncology

Clinical trials at this site (18)

Search interface

Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF)… Pending

2025-525121-13-00 Coronary artery disease 6
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin ( ENLIGHTEN-6 ) Recruiting

2025-523659-73-00 Obesity 5 2026-05-11
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting

2024-519345-30-00 IgA nephropathy 5 2025-11-12
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes Recruiting

2022-502082-22-00 prediabetes 11 2023-09-14
WOEST-3 Recruiting

2022-502140-13-00 Atrial fibrillation Acute coronary syndrome Chronic cor 6 2023-01-11
A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age Ended

2024-519743-15-00 Influenza immunisation 5 2025-10-20
A study on the safety, and immunogenicity of a UTI vaccine in adults 18 through 64 years of age and clinical efficacy in females 18 through … Ended

2024-519319-32-00 Urinary Tract Infections 7 2025-08-27
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended

2023-509762-38-00 Respiratory Syncytial Virus Infections 5 2024-08-01
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended

2023-506457-38-00 Chronic kidney disease (CKD) and hypertension. 5 2024-06-05
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended

2022-503004-24-00 Influenza virus 5 2023-10-20
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination wi… Ended

2023-509354-58-00 Mantle Cell Lymphoma 5 2017-07-14
A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni… Ended

2023-505755-40-00 Chronic kidney disease 4 2024-08-16
A study to find and confirm the dose and assess the safety, reactogenicity and immune response of a vaccine against influenza in healthy you… Ended

2022-502308-66-00 Healthy volunteers (prevention of influenza infection) 7 2023-04-27
A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon… Ended

2023-506981-30-00 Chronic kidney disease in type 2 diabetes mellitus 4 2022-05-25
Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc… Ended

2024-513167-68-00 endometrial cancer 5 2017-11-29